Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026
Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026
Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Company Medical Device

Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console

Fineline Cube Jun 24, 2025

Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...

Policy / Regulatory

NHSA Implements Region-Based Pricing System for Medical Services

Fineline Cube Jun 24, 2025

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Optimizing Medical Service...

Company Deals

Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East

Fineline Cube Jun 24, 2025

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...

Company Deals

Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America

Fineline Cube Jun 24, 2025

Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...

Company Drug

Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment

Fineline Cube Jun 24, 2025

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...

Company Drug R&D

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Fineline Cube Jun 24, 2025

Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...

Company Drug

Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial

Fineline Cube Jun 24, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...

Company Drug

GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC

Fineline Cube Jun 24, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...

Company Drug

Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma

Fineline Cube Jun 24, 2025

France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...

Policy / Regulatory

Beijing Tightens Price Risk Management for Scarce Medications

Fineline Cube Jun 24, 2025

The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...

Company Deals

Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development

Fineline Cube Jun 24, 2025

Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...

Company Deals

Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study

Fineline Cube Jun 24, 2025

US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...

Company Drug

Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease

Fineline Cube Jun 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration

Fineline Cube Jun 24, 2025

US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...

Company Deals

Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan

Fineline Cube Jun 24, 2025

Denovo Biopharma, a US-headquartered precision medicine company with significant operations in China, announced a licensing...

Posts pagination

1 … 114 115 116 … 642

Recent updates

  • C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
  • CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
  • Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.